Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) EBITDA: 2020-2022

Historic EBITDA for Atea Pharmaceuticals (AVIR) over the last 3 years, with Dec 2022 value amounting to -$34.3 million.

  • Atea Pharmaceuticals' EBITDA fell 129.25% to -$34.3 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$116.6 million, marking a year-over-year decrease of 190.89%. This contributed to the annual value of -$168.4 million for FY2024, which is 24.65% down from last year.
  • Per Atea Pharmaceuticals' latest filing, its EBITDA stood at -$34.3 million for Q4 2022, which was down 284.04% from -$8.9 million recorded in Q3 2022.
  • Over the past 5 years, Atea Pharmaceuticals' EBITDA peaked at $117.1 million during Q4 2021, and registered a low of -$42.1 million during Q1 2022.
  • Its 3-year average for EBITDA is $969,091, with a median of -$8.9 million in 2022.
  • Per our database at Business Quant, Atea Pharmaceuticals' EBITDA spiked by 467.31% in 2021 and then crashed by 460.71% in 2022.
  • Over the past 3 years, Atea Pharmaceuticals' EBITDA (Quarterly) stood at $20.6 million in 2020, then soared by 467.31% to $117.1 million in 2021, then slumped by 129.25% to -$34.3 million in 2022.
  • Its last three reported values are -$34.3 million in Q4 2022, -$8.9 million for Q3 2022, and -$31.3 million during Q2 2022.